[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
This study is ongoing.Study 301 (EMBARK), a Phase 3 global, randomised, double-blinded and placebo-controlled study of Elevidys in ambulatory Duchenne patients aged 4-<8 years old.The ENVOL trial (Study 302) a Phase 2 study in children with Duchenne. The study aims to enrol 21 participants who are under 4 years of age, including newborns. Not yet started.The ENVISION trial (Study 303), a Phase 3 study in older ambulatory/non-ambulatory patients which is now recruiting.The EXPEDITION long-term (5 year) follow up study (Study 305) of participants who have received Elevidys in a previous clinical study, which is not yet re...
Source: Roche Investor Update - October 31, 2023 Category: Pharmaceuticals Source Type: news
A chikungunya vaccine is nearing approval. Who will get it?
The first vaccine against the mosquito-borne viral disease chikungunya will likely come to market next month. With the debilitating disease now afflicting more than half the countries in the world and threatening to spread further, the imminent U.S. Food and Drug Administration (FDA) approval of the vaccine is “great news,” says Scott Weaver, a virologist at the University of Texas Medical Branch whose own lab started to work on a chikungunya vaccine nearly 2 decades ago.
The vaccine, made by the French company Valneva, will likely be recommended mainly to U.S. travelers at first. But many expect an FDA approval ...
Source: ScienceNOW - October 30, 2023 Category: Science Source Type: news
Spinal Surgery Redux: Advancing Our Approach to Back Pain
(MedPage Today) -- Lower back pain has been the leading cause of years lived with disability since 1990, and it continues to be a significant concern for public health on a global scale. In the U.S., 72.3 million adults currently suffer from chronic... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 30, 2023 Category: Rheumatology Source Type: news
Mayo Clinic Q and A: Spinal adjustment techniques differ among practitioners
DEAR MAYO CLINIC: What happens during a spinal adjustment? Can professionals other than chiropractors safely do spinal adjustments? ANSWER: Chiropractors commonly perform spinal adjustments, also known as spinal manipulation. However, osteopathic doctors, physical therapists and medical doctors who are specially trained in manipulation may provide the service as well. The purposes of spinal manipulation are to alleviate pain and to optimize spinal motion in regions that are notably stiff or tight. Specific techniques may differ among… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 26, 2023 Category: Databases & Libraries Source Type: news
What Are Potential Complications of a Forceps Delivery?
Discussion
The main outcome of any delivery is to have a healthy mother and healthy child. For millinea, mothers delivered babies with the help of their mothers and learned women without the benefits of potential instrumented interventions when complications arose, and today they are options for some deliveries. Instrumented delivery techniques have markedly decreased maternal and neonatal morbidity and mortality. Instrument delivery techniques in the second stage of labor includes forceps (begun in the 1600s), vacuum delivery (mainly use began in 1950s) and second stage cesarean section (cesarean section being first used ...
Source: PediatricEducation.org - October 23, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Noted New Jersey Chiropractor Joins The Spine & amp; Sports Health Center
Dr. Mike Acanfora will serve as Director of Chiropractic for The Spine & Sports Health Center, welcoming current and new chiropractic patients. BAYONNE, N.J., Oct. 20, 2023 /PRNewswire-PRWeb/ -- The Spine & Sports Health Center, a leading Hudson County based pain management center, is... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 20, 2023 Category: Pharmaceuticals Tags: PER Source Type: news
Mayo Clinic Q and A: How to support a loved one who has chronic pain
DEAR MAYO CLINIC: My spouse suffers from chronic pain after a back injury five years ago. The pain affects his ability to work and enjoy day-to-day activities with our family. Seeing him in pain and not knowing how to help is difficult for me. How can I support him on the challenging days when the pain is more severe and encourage him on the good days? ANSWER: For millions of people, living with chronic pain… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 19, 2023 Category: Databases & Libraries Source Type: news
Enterprise imaging: What is the market opportunity beyond radiology?
The concept of an enterprise imaging strategy was coined over a decade ago, however, it’s only in recent years that the expansion beyond “enterprise radiology” has truly begun. The total market for IT across those nine specialties included in Signify Research’s report reached $6.6 billion in 2022; however, only 20% of market revenue was associated with enterprise deals. When digging deeper into which specialties led the enterprise trend, radiology represented 71% of the total enterprise imaging IT market. As demonstrated in the graph below, radiology and cardiology are expected to continue dominating the market op...
Source: AuntMinnie.com Headlines - October 18, 2023 Category: Radiology Authors: Amy Thompson Tags: PACS/VNA Technology Review Source Type: news
Chronic pain in the lower extremities and low back is associated with recurrent falls in community-dwelling Japanese people aged 40-74 years - Nagashima Y, Kitamura K, Watanabe Y, Kabasawa K, Takahashi A, Saito T, Kobayashi R, Oshiki R, Takachi R, Tsugane S, Yamazaki O, Watanabe K, Nakamura K.
OBJECTIVE: To determine the longitudinal association between chronic pain in the lower extremities and low back and the odds of recurrent falls in middle-aged and older people. DESIGN: A cohort study. SETTING: Communities in Japan. PARTICIPANTS: Pa... (Source: SafetyLit)
Source: SafetyLit - October 16, 2023 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
The roles of depression, life control and affective distress on treatment attendance and perceived disability in chronic back pain sufferers throughout the duration of the condition - Oraison HM, Loton D, Kennedy GA.
The aims of this study were to examine psychological factors that predict treatment seeking and disability over the total duration of experiencing back pain. A sample of 201 adults experiencing chronic back pain was recruited through health professionals a... (Source: SafetyLit)
Source: SafetyLit - October 16, 2023 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news
What the location of your headache REALLY means
London-based GP Dr Ann Nainan says a forehead headache could be caused by eye strain, pain in the temple could be a cluster headache and a tension headache can cause pain at the back of the head. (Source: the Mail online | Health)
Source: the Mail online | Health - October 15, 2023 Category: Consumer Health News Source Type: news
Late-breaking data for Roche ’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS)More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeksThe safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to dateBasel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that inve...
Source: Roche Media News - October 13, 2023 Category: Pharmaceuticals Source Type: news
Late-breaking data for Roche ’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS)More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeksThe safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to dateBasel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that inve...
Source: Roche Investor Update - October 13, 2023 Category: Pharmaceuticals Source Type: news
How COVID-19 Changed Life for People Terrified of Needles
From the moment COVID-19 reached pandemic designation, Joe McDougall had nightmares. Not, like others, about the potential path of the virus, but about the seemingly inevitable moment at which he’d be asked—or held down and forced—to receive a vaccine. McDougall, now 39, is terrified of needles and a global pandemic meant that for the first time since adolescence, he might not be able to avoid them.
[time-brightcove not-tgx=”true”]
Of all of the challenges facing mass COVID-19 vaccination, fear of needles is one of the least acknowledged by public-health campaigns. Even what we know ...
Source: TIME: Health - October 12, 2023 Category: Consumer Health News Authors: Haley Weiss Tags: Uncategorized healthscienceclimate Source Type: news
